HomeSOBI • STO
add
Swedish Orphan Biovitrum AB (publ)
Previous close
kr 316.00
Day range
kr 310.60 - kr 317.00
Year range
kr 241.80 - kr 354.40
Market cap
112.37B SEK
Avg Volume
419.20K
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Financials
Income Statement
Revenue
Net income
| (SEK) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 7.78B | 12.79% |
Operating expense | 3.41B | -3.26% |
Net income | -2.89B | -297.68% |
Net profit margin | -37.22 | -275.24% |
Earnings per share | 6.05 | 40.37% |
EBITDA | 10.32B | 243.54% |
Effective tax rate | 28.12% | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.04B | 74.92% |
Total assets | 66.96B | -7.25% |
Total liabilities | 30.98B | -11.70% |
Total equity | 35.98B | — |
Shares outstanding | 344.66M | — |
Price to book | 3.03 | — |
Return on assets | 10.33% | — |
Return on capital | 13.82% | — |
Cash Flow
Net change in cash
| (SEK) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -2.89B | -297.68% |
Cash from operations | 1.84B | 53.21% |
Cash from investing | -2.70B | -22.57% |
Cash from financing | 857.00M | -0.35% |
Net change in cash | -19.00M | 89.73% |
Free cash flow | 5.71B | 262.88% |
About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Founded
1939
Website
Employees
1,890
